3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
10
Other hematologic neoplasm
8
Genitourinary
7
Gastrointestinal
6
Dermatologic
6
Breast
6
Head & Neck
5
Plasma cell
4
Myeloid
4
CNS
4
Sarcoma
3
Gynecologic
3
Thoracic
2
Tumor-Agnostic
1
Other solid neoplasm
1
Other neoplasm
1
Other
1
Endocrine
1
Classical hematology
1
Conditions
Multiple Endocrine Neoplasia Type 1
1
Depression
1
Alcoholism
1
Interventions
Everolimus
27
pembrolizumab
25
Temozolomide
24
lutetium Lu 177 dotatate
22
Nivolumab
18
Magnetic Resonance Spectroscopy
18
lenvatinib
17
cabozantinib
17
Cisplatin
16
Sunitinib
15
Capecitabine
14
Bevacizumab
14
Specimen Handling
12
Sorafenib
12
trametinib
10
Ipilimumab
10
Etoposide
10
pasireotide
9
dabrafenib
9
Paclitaxel
9
Carboplatin
8
pazopanib
7
lanreotide
7
Octreotide
7
Fluorodeoxyglucose F18
7
anlotinib
6
Irinotecan
6
Injections
6
Doxorubicin
6
surufatinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Therapeutics
×
Endocrine
×
Clear all
NCT00851669
2013-07-16
MEADOW/Bridge
University of Rochester
Phase 2
Completed
91 enrolled